UC
UCM.AU Uscom Ltd
- Market cap
- AUD 3.12M
- P/E
- -
- P/B
- 2.16x
- ROE
- 1,797.0%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.
Is UCM.AU undervalued?
Graham numberThe Graham number of Uscom Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Uscom Ltd fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (1,797.0%), above 20%.
ROA 1/1
Return on assets (712.7%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-51.4%) is below the industry median (24.9%).
Revenue Growth 1/2
Revenue grew 0.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (11.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.2x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Uscom Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Uscom Ltd
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the Spir…
Full company profileUscom Ltd financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Uscom Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.94M | 3.50M | 2.86M | 3.64M | 3.48M | 3.86M | 2.51M | 2.66M | 3.73M | 2.58M | 2.01M |
| Gross Profit | 2.23M | 2.79M | 2.26M | 2.95M | 458K | 782K | -1.21M | -1.03M | 3.12M | 2.23M | -2.00M |
| Operating Income | -1.90M | -1.79M | -1.95M | -1.38M | -1.80M | -1.43M | -2.61M | -2.92M | -2.38M | -3.73M | -3.69M |
| EBITDA | -2.05M | -1.51M | -1.65M | -1.04M | -1.12M | -834K | -1.84M | -2.50M | -1.51M | -2.81M | -3.24M |
| Net Income | -1.92M | -1.80M | -1.96M | -1.39M | -1.33M | -924K | -1.97M | -2.59M | -2.07M | -3.30M | 3.28M |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 5.71M | 4.49M | 5.38M | 4.14M | 5.92M | 5.33M | 7.99M | 5.18M | 5.13M | 3.25M | 461K |
| Total Liabilities | 774K | 708K | 531K | 651K | 2.50M | 2.26M | 2.06M | 2.14M | 2.07M | 3.29M | 278K |
| Shareholders' Equity | 4.94M | 3.78M | 4.84M | 3.49M | 3.42M | 3.08M | 5.94M | 3.04M | 3.06M | -38.2K | 183K |
| Cash & Short-term Investments | 2.84M | 1.71M | 2.49M | 1.21M | 1.92M | 1.71M | 4.70M | 2.18M | 2.52M | 967K | 1.87K |
| Total Debt | - | - | - | - | 1.62M | 1.43M | 1.31M | 1.09M | 989K | 2.26M | 21.1K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.29M | -952K | -1.70M | -1.22M | -283K | 55.0K | -968K | -1.42M | -1.16M | -2.71M | -5.17M |
| Capital Expenditure | 2.51K | 57.6K | 172K | 68.5K | 38.2K | 33.4K | 115K | 152K | 57.5K | 14.2K | 12.00 |
| Free Cash Flow | -1.29M | -1.01M | -1.87M | -1.29M | -321K | 21.6K | -1.08M | -1.58M | -1.22M | -2.72M | -5.17M |
| Ratios | |||||||||||
| ROE | -38.8% | -47.7% | -40.5% | -39.8% | -38.9% | -30.0% | -33.2% | -85.1% | -67.8% | - | 1,797.0% |
| ROA | -33.5% | -40.1% | -36.5% | -33.6% | -22.5% | -17.3% | -24.7% | -50.0% | -40.4% | -101.7% | 712.7% |
| Net Profit Margin | -65.2% | -51.5% | -68.5% | -38.1% | -38.3% | -24.0% | -78.6% | -97.2% | -55.7% | -128.1% | 163.6% |
| Debt to Equity | - | - | - | - | 0.47x | 0.46x | 0.22x | 0.36x | 0.32x | - | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Uscom Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 620K | 0.00 | - |
| 2022 | AUD 3.99M | 0.02 | - |
| 2021 | AUD 293K | 0.00 | - |
| 2020 | AUD 253K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Uscom Ltd
- Insiders 82.96%
- Institutions 0.00%
- Public & others 17.04%
- Shares outstanding 260M
- Free float 58.4M
Uscom Ltd company profile
- Company name
- Uscom Ltd
- Ticker
- UCM.AU
- ISIN
- AU000000UCM2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 66 Clarence Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9247 4144
- Website
- uscom.com.au
About Uscom Ltd
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Uscom Ltd management
3- Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med)Founder, Executive Chairman, CEO & Chief Scientist · born 1953
- Mr. Brett Thomas Crowley B.Com., C.A., DipLawCompany Secretary & Independent Non-Executive Director · born 1957
- Mr. Nicholas Schicht BEngGeneral Manager · born 1966